Published in Health Qual Life Outcomes on October 12, 2011
Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial. Ann Oncol (2013) 1.76
Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid. Support Care Cancer (2013) 1.12
Qualitative research into the symptom experiences of adult cancer patients after treatments: a systematic review and meta-synthesis. Support Care Cancer (2012) 0.91
Patient-reported outcome labeling claims and measurement approach for metastatic castration-resistant prostate cancer treatments in the United States and European Union. Health Qual Life Outcomes (2014) 0.81
Development of a preliminary nomogram to predict progression of bone scan for castration-resistant prostate cancer. Onco Targets Ther (2015) 0.77
Longitudinal analysis of pain in patients with metastatic prostate cancer using natural language processing of medical record text. J Am Med Inform Assoc (2012) 0.76
Patient-reported outcomes in metastatic castration-resistant prostate cancer. Nat Rev Clin Oncol (2016) 0.76
Diagnostic imaging to detect and evaluate response to therapy in bone metastases from prostate cancer: current modalities and new horizons. Eur J Nucl Med Mol Imaging (2016) 0.75
Health-related quality of life effects of enzalutamide in patients with metastatic castration-resistant prostate cancer: an in-depth post hoc analysis of EQ-5D data from the PREVAIL trial. Health Qual Life Outcomes (2017) 0.75
Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes (2006) 26.32
The McGill Pain Questionnaire: major properties and scoring methods. Pain (1975) 14.75
The short-form McGill Pain Questionnaire. Pain (1987) 14.40
Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain (2005) 11.80
Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain (2007) 8.89
Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol (2000) 7.94
Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev (2001) 6.57
When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain (1995) 5.97
Pain: a review of three commonly used pain rating scales. J Clin Nurs (2005) 5.86
What is an adequate sample size? Operationalising data saturation for theory-based interview studies. Psychol Health (2010) 5.31
Prevalence of undertreatment in cancer pain. A review of published literature. Ann Oncol (2008) 4.70
The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol (2005) 3.56
Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol (2007) 3.23
Increasing the reliability and validity of pain intensity measurement in chronic pain patients. Pain (1993) 2.57
The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain (2008) 2.48
Pain predicts overall survival in men with metastatic castration-refractory prostate cancer. J Clin Oncol (2008) 2.31
Developing patient-reported outcome measures for pain clinical trials: IMMPACT recommendations. Pain (2006) 2.23
PRO development: rigorous qualitative research as the crucial foundation. Qual Life Res (2010) 1.92
Patient-reported outcomes: conceptual issues. Value Health (2007) 1.72
Worst, average or current pain in the Brief Pain Inventory: which should be used to calculate the response to palliative radiotherapy in patients with bone metastases? Clin Oncol (R Coll Radiol) (2007) 1.60
Docetaxel, vinorelbine, and zoledronic acid as first-line treatment in patients with hormone refractory prostate cancer: a phase II study. Eur Urol (2007) 1.46
The Brief Pain Inventory and its "pain at its worst in the last 24 hours" item: clinical trial endpoint considerations. Pain Med (2010) 1.40
Effect of bisphosphonates on pain and quality of life in patients with bone metastases. Nat Clin Pract Oncol (2009) 1.40
Pattern and quality of care of cancer pain management. Results from the Cancer Pain Outcome Research Study Group. Br J Cancer (2009) 1.37
The measurement of pain from metastatic bone disease: capturing the patient's experience. Clin Cancer Res (2006) 1.35
Natural history and treatment of bone complications in prostate cancer. Eur Urol (2006) 1.26
A survey of pain in patients with advanced cancer. J Pain Symptom Manage (1996) 1.07
Comparison of numerical and verbal rating scales to measure pain exacerbations in patients with chronic cancer pain. Health Qual Life Outcomes (2010) 1.03
A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer. Health Technol Assess (2007) 1.02
Assessing persistent cancer pain: a comparison of current pain ratings and pain recalled from the past week. J Pain Symptom Manage (2008) 0.99
Patient perceptions associated with chemotherapy-induced peripheral neuropathy. Clin J Oncol Nurs (2010) 0.98
Prostate cancer metastases to bone: pathophysiology, pain management, and the promise of targeted therapy. Eur J Cancer (2005) 0.93
A validation study of the WHO analgesic ladder: a two-step vs three-step strategy. Support Care Cancer (2005) 0.91
Development of a cancer pain prognostic scale. J Pain Symptom Manage (2002) 0.85
Estimating minimally important differences for the worst pain rating of the Brief Pain Inventory-Short Form. J Support Oncol (2011) 0.85
Emerging therapies in castrate-resistant prostate cancer. Curr Urol Rep (2010) 0.83
Constructing a conceptual framework of patient-reported outcomes for metastatic hormone-refractory prostate cancer. Value Health (2010) 0.82
Clodronate for treatment of bone metastases in hormone refractory prostate cancer. Int Braz J Urol (2005) 0.81
Experiences of symptoms in men with hormone refractory prostate cancer and skeletal metastases. Eur J Oncol Nurs (2008) 0.77
Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer. J Clin Oncol (2013) 1.95
Differences in treatment patterns among patients with castration-resistant prostate cancer treated by oncologists versus urologists in a US managed care population. Cancer Manag Res (2011) 1.81
Optimal recall periods for patient-reported outcomes: challenges and potential solutions. Curr Med Res Opin (2009) 1.70
Adherence to oral tyrosine kinase inhibitor therapies in chronic myeloid leukemia. Leuk Res (2012) 1.59
Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone. Cancer (2012) 1.16
EGFR mutation testing in patients with advanced non-small cell lung cancer: a comprehensive evaluation of real-world practice in an East Asian tertiary hospital. PLoS One (2013) 1.13
Burden of post-herpetic neuralgia in a sample of UK residents aged 50 years or older: findings from the Zoster Quality of Life (ZQOL) study. Health Qual Life Outcomes (2014) 1.04
Pediatric asthma: improving management to reduce cost of care. J Manag Care Pharm (2004) 1.00
Interviewing to develop Patient-Reported Outcome (PRO) measures for clinical research: eliciting patients' experience. Health Qual Life Outcomes (2014) 0.97
Can managed care organizations partner with manufacturers for comparative effectiveness research? Am J Manag Care (2008) 0.97
The safety and clinical benefit of budesonide/formoterol pressurized metered-dose inhaler versus budesonide alone in children. Allergy Asthma Proc (2010) 0.92
Comparison of adjustable- and fixed-dose budesonide/formoterol pressurized metered-dose inhaler and fixed-dose fluticasone propionate/salmeterol dry powder inhaler in asthma patients. J Allergy Clin Immunol (2008) 0.92
Once- vs twice-daily budesonide/formoterol in 6- to 15-year-old patients with stable asthma. Pediatrics (2010) 0.91
Targeting treatment-resistant breast cancer stem cells with FKBPL and its peptide derivative, AD-01, via the CD44 pathway. Clin Cancer Res (2013) 0.90
Factors influencing patient decisions about the use of asthma controller medication. Ann Allergy Asthma Immunol (2007) 0.89
Onset of effect of budesonide and formoterol administered via one pressurized metered-dose inhaler in patients with asthma previously treated with inhaled corticosteroids. Ann Allergy Asthma Immunol (2008) 0.88
Development and validation of the Chronic Obstructive Pulmonary Disease Assessment Questionnaire (COPD-AQ). Prim Care Respir J (2009) 0.86
Upper limb deep vein thrombosis due to Langer's axillary arch. J Vasc Surg (2011) 0.85
Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration-resistant prostate cancer. Prostate (2011) 0.85
Burden of herpes zoster in the UK: findings from the zoster quality of life (ZQOL) study. BMC Infect Dis (2014) 0.85
Effects of budesonide inhalation suspension compared with cromolyn sodium nebulizer solution on health status and caregiver quality of life in childhood asthma. Pediatrics (2003) 0.84
Relationship between symptom change, objective tumor measurements, and performance status during chemotherapy for advanced lung cancer. Clin Lung Cancer (2008) 0.83
The penile cuff test: A clinically useful non-invasive urodynamic investigation to diagnose men with lower urinary tract symptoms. Indian J Urol (2009) 0.83
"Not just little adults": qualitative methods to support the development of pediatric patient-reported outcomes. Patient (2013) 0.83
Budesonide turbuhaler delivered once daily improves health-related quality of life in adult patients with non-steroid-dependent asthma. Allergy Asthma Proc (2003) 0.82
Patient-reported outcomes in adults with moderate to severe asthma after use of budesonide and formoterol administered via 1 pressurized metered-dose inhaler. Ann Allergy Asthma Immunol (2008) 0.81
Content validity of the PedsQL™ 3.2 Diabetes Module in newly diagnosed patients with Type 1 diabetes mellitus ages 8-45. Qual Life Res (2012) 0.81
The effect of budesonide and formoterol in one pressurized metered-dose inhaler on patient-reported outcomes in adults with mild-to-moderate persistent asthma. Curr Med Res Opin (2008) 0.80
An instrument assessing satisfaction with iron chelation therapy: Psychometric testing from an open-label clinical trial. Adv Ther (2010) 0.80
Budesonide Turbuhaler delivered once daily improves health-related quality of life and maintains improvements with a stepped-down dose in adults with mild to moderate asthma. Ann Allergy Asthma Immunol (2003) 0.79
Challenges in quantifying the patient-reported burden of herpes zoster and post-herpetic neuralgia in the UK: learnings from the Zoster Quality of Life (ZQOL) study. BMC Res Notes (2013) 0.79
A phase II, randomized, multicenter study to assess the efficacy, safety, and tolerability of zibotentan (ZD4054) in combination with pemetrexed in patients with advanced non-small cell lung cancer. Cancer Chemother Pharmacol (2010) 0.79
Inhaled corticosteroids vs leukotriene receptor antagonists: health care costs across varying asthma severities. Ann Allergy Asthma Immunol (2006) 0.78
Real world impact of epidermal growth factor receptor mutation status on treatment patterns in patients with non-small cell lung cancer. Lung Cancer (2013) 0.78
Cost effectiveness of asthma controller therapies: influence of disease severity and other variables. Manag Care Interface (2005) 0.77
Development of the asthma treatment satisfaction measure. Curr Med Res Opin (2009) 0.77
Once-daily budesonide inhalation powder (Pulmicort Turbuhaler) improves health-related quality of life in adults previously receiving inhaled corticosteroids. Adv Ther (2004) 0.77
Efficacy and tolerability of once-daily budesonide/formoterol pressurized metered-dose inhaler in adults and adolescents with asthma previously stable with twice-daily budesonide/ formoterol dosing. Ann Allergy Asthma Immunol (2009) 0.76
Measuring the symptoms of pediatric constipation and irritable bowel syndrome with constipation: expert commentary and literature review. Patient (2014) 0.76
European content validation of the Self-Assessment Goal Achievement (SAGA) questionnaire in patients with overactive bladder. Int Urogynecol J (2013) 0.75
Caregiver preferences for pediatric asthma treatment delivery systems. Adv Ther (2007) 0.75